Real-World Comparison of Oral Versus Injectable Semaglutide for the Reduction of Hemoglobin A<sub>1C</sub> and Weight in Patients with Type 2 Diabetes
In this study, patients with T2D who received oral semaglutide demonstrated greater reductions in HbA<sub>1C</sub>, whereas those treated with injectable semaglutide had greater reductions in weight, although there were no statistically significant reductions in HbA<sub>1C</sub> or weight between the 2 formulations. Rates of AEs and discontinuation were more common in the oral semaglutide group.
Authors
- Kelly Diehl
- Samantha Heacock (ORCID: https://orcid.org/0000-0002-7310-6880)
- Shi-Dou Lin (ORCID: https://orcid.org/0000-0001-9880-7539)
- Maria Pinto (ORCID: https://orcid.org/0009-0005-0525-8750)
- Lillian Brennan
Institutions
- University of Rochester Medical Center (US)
Publication Details
- Journal
- Journal of Pharmacy Technology
- Published
- 2024-11-05
- DOI
- https://doi.org/10.1177/87551225241289959
- Citations
- 7
- Primary Topic
- Diabetes Treatment and Management
- Type
- article
- Field-Weighted Citation Impact
- 2.50
Funders
- University of Rochester
- Medical Center, University of Rochester